Articles tagged with Neurodegenerative Diseases
Researchers from the University of Calgary and international collaborators explored the zoonotic potential of CWD in controlled laboratory settings. The study found that infectious prions can still be present and transmissible even without obvious clinical signs, highlighting the need for continued surveillance and research.
Researchers from Florida Atlantic University have identified a key immune pathway that appears to drive damaging inflammation in Huntington disease. Blocking this pathway reduced brain inflammation, protected neurons, and improved movement in a humanized mouse model of the disease.
A new AI tool, AIDD, combines brain scans with machine learning to accurately diagnose two common forms of dementia. The tool showed near-perfect accuracy in identifying Alzheimer's disease and dementia with Lewy bodies, offering a promising future for clinicians.
A large Japanese study found that maintaining a healthier profile with lower lifestyle and health risks can significantly lower dementia risk in people with one or no APOE ε4 alleles. However, individuals carrying two APOE ε4 alleles may require different preventive or therapeutic approaches.
Researchers have identified an experimental molecule called OLE that helps restore microglia's protective function against Alzheimer's disease. The compound reduces beta-amyloid plaque size and toxicity, improving cognitive performance in memory tests.
Andrew Yang's research has reshaped scientific understanding of the blood-brain barrier and its role in brain health and disease. His latest study reveals new potential treatment targets for neurological diseases, normal aging, and sleep.
Researchers found biomarkers for Alzheimer's disease that correlated with minor cognitive differences in midlife adults. These biomarkers, measuring tau and amyloid plaque, were associated with a greater chance of cognitive decline, particularly in processing speed and executive function.
Researchers suggest targeting upstream metabolic nodes to regulate mTORC1 signaling and autophagy defects in neurodegenerative diseases. Acetyl-CoA production modulation and p300 acetylation activity regulation may also hold therapeutic promise.
A new brain imaging test can detect Alzheimer's disease pathology in twice as many people before symptoms appear. The test uses a new tau PET tracer that identifies more tau-positive cases than the current standard, leading to better decisions about who is on an Alzheimer's trajectory.
Researchers found that impaired virtual reality path integration was closely tied to brain structure and biomarkers associated with neurodegeneration. This suggests that VR-based navigation errors may reveal hidden changes in the brain long before symptoms arise, making it a promising behavioral marker for preclinical Alzheimer's disease.
A new approach combines MRI scans and AI tools to measure fluid flow in the brain, shedding light on the glymphatic system’s mechanics. The study reveals two main ways the system washes away particles, with one way moving faster than the other.
A new study found irisin reduces clinical symptoms and neuron loss in a mouse model of MS. Irisin also protects neurons from inflammation-driven neurodegeneration.
A medical school team has been awarded a $6 million grant to develop gene-replacement preclinical models of Parkinson's disease. The goal is to better understand the disease and support early-stage therapeutic research by identifying critical pathogenic mechanisms.
Researchers developed a technique that uses RNA origami to analyze sections of RNA, allowing for accurate sizing of repeat expansions in genetic disorders. The method shows promise for fast and affordable testing in clinical settings.
Researchers mapped HuD-bound mRNAs across embryonic and adult mouse brains, finding shared biological pathways. The study suggests that adult neurons use an embryonic
A new statistical approach used in Alzheimer's disease trials may exaggerate the link between amyloid reduction and cognitive benefits of new drugs. Researchers found that combining large groups of patients can hide variability and make it appear as if reducing amyloid is more predictive of cognitive benefit than it actually is.
A recent study by Dr. Walaa Oweis and Prof. Eran Meshorer found that protein clumps in the brain may actually be protecting neurons from stress, acting as a vital quarantine system.
Researchers analyzed brain tissue from MSA patients and found that the immune cells known as microglia appear to be exhausted or dysfunctional in later stages of the disease. The study suggests that an overactive immune system may contribute to the development of MSA, providing a potential target for future treatment.
A three-year research project aims to identify the molecular pathways linking exposure to pesticides and air pollution to Parkinson's disease development and progression. The study will analyze human stem cells, animal models, and genetic analyses to understand how environmental toxins trigger disease onset.
Researchers identified GPNMB as a key molecule driving brain cell damage in Parkinson's disease. Blocking this protein with antibodies may help slow disease progression by interrupting the spread of toxic brain proteins.
The Pittsburgh Institute for Neurodegenerative Diseases will investigate how environmental exposures cause neurodegeneration and develop methods to prevent or mitigate these exposures. The project aims to improve diagnostics and future therapies for Parkinson's disease, a condition characterized by heterogeneity across individuals.
A review from Florida Atlantic University links obesity to Alzheimer's disease through disruptions in metabolism, highlighting the importance of mitochondrial function and gut-brain axis balance. Early detection and whole-body prevention may become possible through monitoring metabolic health.
Researchers developed a new photonic material using lead iodide, enabling high-speed data transmission in the terahertz frequency range. The material confines light within submicrometer regions, paving the way for integrated photonic circuits that could replace or complement electronic circuits.
Scientists have discovered a protective brain pathway that preserves dopamine-producing neurons and reduces degeneration in female models with Parkinson's disease. The study suggests that strengthening this pathway could help slow the progression of the disease, offering new potential for treatment.
Researchers studying RNA pollution's impact on aging brains seek to develop therapeutic strategies for neurodegenerative diseases like Alzheimer's. Sanford Burnham Prebys scientist Anne Bang will use advanced robotics to test thousands of compounds.
A new review proposes a prevention-focused framework for understanding Parkinson's disease risk, highlighting the role of early-life vulnerability, environmental exposures, and resilience factors. The study suggests that susceptibility to PD may begin earlier in life through interactions between biology and environment.
Researchers at UTHealth Houston have been awarded a three-year, $7.8 million grant to better understand how Parkinson’s disease occurs in the brain. The project aims to identify proteins and cellular pathways involved in brain damage, with the goal of developing novel strategies for intervention.
A global research network, led by ASAP and MJFF, is expanding its efforts to map the biological blueprint of Parkinson's disease and develop a standardized toolkit of global research resources. This expansion aims to accelerate the development of personalized therapies by understanding the disease's inherent heterogeneity.
Researchers at Indiana University School of Medicine developed a new method to analyze brain energy network patterns, revealing insights into Alzheimer's disease progression. The study found that brain networks reorganize as the disease progresses, with memory and language functions showing increased metabolic demand in early stages.
FINGERS-7B integrates lifestyle, clinical, genomic, and proteomic data to discover multi-omic biomarkers for preclinical Alzheimer's. The model delivers 4× more accurate preclinical diagnosis and 130% better responder stratification than prior art.
A randomized clinical trial examined the impact of Alzheimer's disease and related dementias (ADRD) screening in older adults on family members. The study found that primary care screenings did not worsen quality of life, depression, or anxiety over two years.
Researchers found three distinct trajectories of cognitive decline: stable, slow and fast decline. Biomarker data showed that participants who declined faster had higher P-tau217 levels and smaller hippocampi.
The researchers will investigate novel therapies to protect the aging brain from neurodegenerative diseases by eliminating RNA pollution. They will map out signatures of RNA pollution across over 200 cell lines and patient biofluids to understand its effects.
A phase 1 clinical trial has started enrolling patients with symptoms of prion disease, evaluating the safety and tolerability of a small interfering RNA targeting the prion protein. The trial aims to slow disease progression and is supported by NeuroNEXT, a program of the National Institute of Neurological Disorders and Stroke.
A recent study has found that epigenetic clocks are associated with cognitive impairment and dementia, but only specific epigenetic markers related to smoking exposure are linked to neurodegenerative changes. The study suggests that measures of epigenetic age acceleration capture different aspects of biological aging.
A new study found comprehensive evidence that weight-loss GLP-1 receptor agonists like semaglutide reduce amyloid-beta and tau buildup in the brain. Consistent reductions were seen in animal and cell studies, with liraglutide showing the most positive effects.
A national study found that people with severe strokes have a five times higher odds of developing dementia. Stroke severity also affects thinking and memory after stroke, highlighting the need for close monitoring and treatment of dementia risk factors.
Researchers will use DNA-encoded chemical libraries and artificial intelligence to screen hundreds of millions of potential drug compounds, identifying those most likely to succeed in treating Alzheimer's. The project aims to shorten the timeline for identifying new treatments, bringing them to patients faster and with greater precision.
tACS modulates brain oscillations, induces synaptic plasticity, and regulates neurotransmitter release to alleviate symptoms of various neuropsychiatric conditions. Personalized approaches are essential for treatment efficacy.
A study from the University of São Paulo reveals that neurodegenerative processes extend beyond the central nervous system, affecting various targets throughout the body. The researchers identified over 9,000 autoantibodies linked to immune status, neurological damage, and symptoms specific to each disease.
Researchers discovered that small lesions in white matter can trigger a response in connected grey matter, leading to neuronal activity fall, microglia activation, and synapse loss. However, this response is part of the repair process, essential for brain regeneration.
A study at University at Buffalo found that L-arginine enhances protein droplet stability, preventing fibril conversion and preserving microtubule assembly. This naturally occurring small molecule may help guide therapies targeting fibril formation in Alzheimer's disease.
Researchers discover cancer-driving genes in microglia of Alzheimer's patients, suggesting a link between blood cancers and the neurodegenerative disease. The findings could lead to new diagnostic tools and therapeutic options for Alzheimer's.
Researchers from Johns Hopkins Medicine have developed mini brain-like structures grown in the lab that could be used to evaluate how patients with Alzheimer's disease respond to certain drugs. The study found that tiny particles secreted by these brain tissues may contain cellular information that could help scientists find new biomar...
A study by UC San Diego researchers identified CgA-centered stress-response pathways as key drivers of cognitive resilience in individuals with asymptomatic Alzheimer's disease. The findings also introduce a new framework to accelerate the discovery of preventive therapies for Alzheimer's disease.
A new study reveals that people with Parkinson's disease have a distinct gut microbiome, as do those at genetic risk but without symptoms. This could lead to early detection and potential prevention strategies.
Researchers found SIRT6 is essential for maintaining protein homeostasis, regulating the protein life cycle to prevent protein aggregates that contribute to neurodegenerative diseases. Reduced SIRT6 levels play a critical role in aging and age-related neurodegeneration.
NYU Langone Health experts present platform talks on practical strategies to counter medical misinformation, phase 3 X-TOLE2 trial results for novel epilepsy treatment, and exploring healthcare accessibility for patients with disabilities. The Department of Neurology features over 80 presentations from faculty members.
Researchers identify senescent macrophages as a driver of fatty liver disease, inflammation and aging. Clearing these cells reversed liver damage in mice on unhealthy diets.
A new Cochrane review of 17 clinical trials found that anti-amyloid Alzheimer's drugs have no significant impact on cognitive decline or dementia severity, but may increase the risk of brain swelling and bleeding. The evidence suggests that these drugs are unlikely to provide clear benefit to patients.
Researchers develop molecular tool called SynTrogo, which enables selective dismantling of synaptic connections in brain circuits. By harnessing astrocytes, the system reduces synapse number while strengthening remaining connections, leading to enhanced long-term potentiation and improved memory.
Researchers developed a nasal spray that reversibly reduces brain inflammation, restores cellular power plants, and improves memory. The treatment bypasses the brain's protective shield through intranasal delivery, suppressing chronic inflammation and promoting successful brain aging.
A new study from Edith Cowan University found that higher sodium intake is associated with a faster decline in episodic memory in men. The study of over 1,200 participants suggests that diets high in salt may have broader cognitive impacts than previously understood.
A team led by Jiefu Li developed a new method to examine proteins lining the inside surface of blood vessels, revealing two proteins and pathways that play a role in opening and closing the blood-brain barrier. This discovery could help scientists understand how the barrier functions and develop better ways to deliver medicines for neu...
A new study by POSTECH researchers found that the protein tau interacts with DNA during cell division, forming condensates that capture microtubules. This interaction affects chromosome alignment and can lead to cellular abnormalities even in healthy cells.
Researchers at the University of Waterloo have discovered a safer and more effective way to treat Alzheimer's disease by combining anti-amyloid antibodies with molecules found in grapes, berries, peanuts, and turmeric. This combination approach neutralizes amyloid protein clumping in the brain, leading to better outcomes.
The Barrow Neuro Analytics Center has nearly doubled its dedicated research space to 18,000 square feet, supporting growing neurological research programs. Researchers at the center are globally renowned for their work on Parkinson's disease, Alzheimer's, and other neurological disorders using data-focused methods.
Scientists at NTU Singapore found that glycerol-3-phosphate acyltransferase (GPAT) amplifies α-synuclein toxicity by altering fat metabolism in brain cells. Targeting GPAT activity may offer a new strategy for treating Parkinson's disease.
A Georgia State University study found that Alzheimer's affects men's and women's brains differently, with women showing steeper and more widespread decline. The research suggests that brain compensation mechanisms may help maintain cognitive performance in women earlier in the disease.
Gladstone Institutes investigator Ryan Corces receives $750,000 to investigate unknown genetic variants contributing to Alzheimer's disease. He aims to identify new drivers and therapeutic targets using artificial intelligence and CRISPR tools.